Bausch Health Cos Inc. (BHC)
(Delayed Data from NYSE)
$17.19 USD
+0.04 (0.23%)
Updated Jul 10, 2020 04:00 PM ET
4-Sell of 5 4
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.04% 17.51% 9.10% 4.64% 1.64% 10.44% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
A Value C Growth B Momentum A VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Company Summary
Based in Laval, Canada, Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
The company restructured its business and sold the units that were not performing well. Bausch has narrowed its focus on seven recently launched or expected to be launched products, pending completion of testing and receipt of FDA approval.
The company ...
Company Summary
Based in Laval, Canada, Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
The company restructured its business and sold the units that were not performing well. Bausch has narrowed its focus on seven recently launched or expected to be launched products, pending completion of testing and receipt of FDA approval.
The company conducts its business in four operating segments:
- The Bausch + Lomb/International segment consists of sales of pharmaceutical products in The United States, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the vision care, surgical, consumer and ophthalmology Rx products. The segment generated 55.1% of total revenues in 2019.
- The Salix segment consists of sales in the U.S. of gastrointestinal products. The segment generated 23.5% of total revenues in 2019.
- The Ortho Dermatologics segment consists of: sales Ortho Dermatologics in the United States (dermatological) products and (ii) global sales of Solta medical dermatological devices. The segment generated 6.5% of total revenues in 2019.
- The Diversified Products segment consists of sales of pharmaceutical products in the areas of neurology and certain other therapeutic classes in the United States, generic products, and dentistry products.The segment generated 14.9% of total revenues in 2019.
Revenues came in at $8.6 billion in 2019, up 3% from 2018.
General Information
Bausch Health Cos Inc
2150 ST. ELZEAR BLVD. WEST
LAVAL, A8 H7L 4A8
Phone: 514-744-6792
Fax: 514-744-6272
Web: http://www.bauschhealth.com
Email: ir@bauschhealth.com
| Industry | Medical - Generic Drugs |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 6/30/2020 |
| Next EPS Date | 8/4/2020 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.65 |
| Current Year EPS Consensus Estimate | 3.73 |
| Estimated Long-Term EPS Growth Rate | 10.70 |
| Next EPS Report Date | 8/4/2020 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 17.15 |
| 52 Week High | 31.97 |
| 52 Week Low | 11.15 |
| Beta | 1.26 |
| 20 Day Moving Average | 3,749,368.00 |
| Target Price Consensus | 30.23 |
| 4 Week | 1.00 |
| 12 Week | 1.60 |
| YTD | -42.55 |
| 4 Week | -4.80 |
| 12 Week | -10.70 |
| YTD | -41.25 |
| Shares Outstanding (millions) | 354.83 |
| Market Capitalization (millions) | 6,099.49 |
| Short Ratio | 1.00 |
| Last Split Date | 10/16/2000 |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 4.61 |
| Trailing 12 Months | 4.04 |
| PEG Ratio | 0.43 |
| vs. Previous Year | -13.59% |
| vs. Previous Quarter | -22.61% |
| vs. Previous Year | -0.20% |
| vs. Previous Quarter | -9.53% |
| Price/Book | 7.66 |
| Price/Cash Flow | 1.64 |
| Price / Sales | 0.71 |
| 6/30/20 | NA |
| 3/31/20 | 84.58 |
| 12/31/19 | 68.06 |
| 6/30/20 | NA |
| 3/31/20 | 4.68 |
| 12/31/19 | 4.78 |
| 6/30/20 | NA |
| 3/31/20 | 1.13 |
| 12/31/19 | 1.12 |
| 6/30/20 | NA |
| 3/31/20 | 0.90 |
| 12/31/19 | 0.94 |
| 6/30/20 | NA |
| 3/31/20 | 17.65 |
| 12/31/19 | 18.13 |
| 6/30/20 | NA |
| 3/31/20 | -21.96 |
| 12/31/19 | -20.79 |
| 6/30/20 | NA |
| 3/31/20 | -22.02 |
| 12/31/19 | -21.36 |
| 6/30/20 | NA |
| 3/31/20 | 2.24 |
| 12/31/19 | 3.22 |
| 6/30/20 | NA |
| 3/31/20 | 2.12 |
| 12/31/19 | 2.20 |
| 6/30/20 | NA |
| 3/31/20 | 0.00 |
| 12/31/19 | 21.71 |
| 6/30/20 | NA |
| 3/31/20 | 0.00 |
| 12/31/19 | 95.60 |